ARTICLE | Company News
Archemix, Dicerna, miRagen deal
July 27, 2009 7:00 AM UTC
Archemix announced a pair of deals to use its aptamers to facilitate intracellular delivery of RNA-based therapeutics. Archemix and miRagen will develop conjugated aptamer-miRNA. miRagen has an option to negotiate for exclusive rights to develop and commercialize resulting therapeutics. Further terms were not disclosed. ...